Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes - Top-Institutions - MDSpire

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • By

  • Abiola Bolarinwa

  • Madhu Nagaraj

  • Saurabh Zanwar

  • Nadine Abdallah

  • P. Leif Bergsagel

  • Moritz Binder

  • Francis Buadi

  • Saurabh Chhabra

  • Joselle Cook

  • David Dingli

  • Angela Dispenzieri

  • Morie A. Gertz

  • Wilson Gonsalves

  • Suzanne Hayman

  • Prashant Kapoor

  • Taxiarchis Kourelis

  • Nelson Leung

  • Yi Lin

  • Eli Muchtar

  • Ricardo Parrondo

  • Vivek Roy

  • Taimur Sher

  • Mustaqeem Siddiqui

  • Rahma Warsame

  • Amie Fonder

  • Miriam Hobbs

  • Yi Lisa Hwa

  • Michelle Rogers

  • Udit Yadav

  • J. Erin Wiedmeier-Nutor

  • Linda B. Baughn

  • S. Vincent Rajkumar

  • Rafael Fonseca

  • Sikander Ailawadhi

  • Shaji Kumar

  • April 4, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloma Research

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma

  • #4

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Myeloma Research

Original Source(s)

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes

  • by Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, P. Leif Bergsagel, Moritz Binder, Francis Buadi, Saurabh Chhabra, Joselle Cook, David Dingli, Angela Dispenzieri, Morie A. Gertz, Wilson Gonsalves, Suzanne Hayman, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Ricardo Parrondo, Vivek Roy, Taimur Sher, Mustaqeem Siddiqui, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Michelle Rogers, Udit Yadav, J. Erin Wiedmeier-Nutor, Linda B. Baughn, S. Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar

  • April 4, 2025

Related Content

Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis

Why are long-lived plasma cells long-lived?

Differential expression of immune activation markers in T cells from patients with multiple myeloma